(Q44383236)

English

High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma

scientific article published in March 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

1 reference

based on heuristic

inferred from title

author name string

Rossi HA

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Becker PS

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Emmons RV

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Westervelt P

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Levy W

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Liu Q

6

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Clark Y

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Ballen K

8

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

language of work or name

0 references

publication date

1 March 2003

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

441-446

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703874

0 references

Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

21 January 2018

Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

21 January 2018

Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

21 January 2018

Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

21 January 2018

Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

21 January 2018

Autologous bone marrow transplantation for patients with poor-prognosis lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

21 January 2018

HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

21 January 2018

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

21 January 2018

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

21 January 2018

High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

21 January 2018

Intensified preparative regimens and allogeneic transplantation in refractory or relapsed intermediate and high grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

21 January 2018

The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

21 January 2018

Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

21 January 2018

High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

21 January 2018

A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

21 January 2018

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

21 January 2018

Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic marrow transplantation for refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

7 January 2021

based on heuristic

inferred from DOI database lookup

High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

7 January 2021

based on heuristic

inferred from DOI database lookup

Which treatment for mantle-cell lymphoma patients in 1998?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

7 January 2021

based on heuristic

inferred from DOI database lookup

High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

7 January 2021

based on heuristic

inferred from DOI database lookup

Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703874

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1703874

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44383236&oldid=2020745211"